CDT Equity (CDT) Assets Average (2022 - 2026)
CDT Equity's (CDT) quarterly Assets Average came in at $66.4 million in Q1 2026, up 2231.58% YoY from $2.8 million in Q1 2025, and up 834.64% on a QoQ basis from $7.1 million in Q4 2025.
CDT Equity (CDT) Assets Average (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Assets Average data on file, last reported at $66.4 million in Q1 2026.
- Quarterly Assets Average rose 2231.58% year-over-year to $66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.4 million (up 2231.58% YoY) and the FY2025 annual result came in at $4.9 million, down 13.79% from the prior year.
- Assets Average rose to $66.4 million in Q1 2026, from $7.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $136.7 million in Q3 2022 to a low of $255500.0 in Q1 2023.
- A 5-year average of $31.0 million and a median of $6.1 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average sank 99.63% — and 2024, when it jumped 2275.93%.
- Tracing CDT's Assets Average over 5 years: stood at $68.4 million in 2022, then tumbled by 85.94% to $9.6 million in 2023, then slumped by 62.65% to $3.6 million in 2024, then soared by 97.63% to $7.1 million in 2025, then surged by 834.64% to $66.4 million in 2026.
- The last three Assets Average figures came in at $66.4 million (Q1 2026), $7.1 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 126.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.90 Mn |
| Mar 31, 2026 | 66.37 Mn |
| Dec 31, 2025 | 7.10 Mn |
| Sep 30, 2025 | 5.03 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 9.62 Mn |
| Sep 30, 2023 | 6.46 Mn |
| Jun 30, 2023 | 703,000.00 |
| Mar 31, 2023 | 255,500.00 |
| Dec 31, 2022 | 68.43 Mn |
| Sep 30, 2022 | 136.66 Mn |
| Jun 30, 2022 | 136.50 Mn |
| Mar 31, 2022 | 68.37 Mn |